FAST NEWS: Investment Loss Undermines Simcere Pharma’s Profit
The latest: Simcere Pharmaceutical Group Ltd. (2096.HK) on Wednesday reported its revenue grew 27.3% to 2.7 billion yuan ($389 million) in the first half of the year, while its net profit…
FAST NEWS: New Injectable Drug from Simcere Pharma Approved For Marketing In China
The latest: Simcere Pharmaceutical Group Ltd. (2096.HK) announced Wednesday it will market Cosela, a cyclin-dependent kinase CDK4/6 inhibitor developed by the group with G1 Therapeutics, in China after receiving conditional approval from the…
Drug Maker Simcere Ditches Cell Therapy to Focus on Oncology
Company sells money-losing Simgene unit for $16 million, following recent deals to commercialize two new cancer drugs in China Key Takeaways: New China licensing deals and oncology focus come amid…
RELATED ARTICLES
-
Profit setback for Simcere Pharma in novel drugs quest
2096.HK -
Novel drugs lift Sino Biopharm earnings, easing price-cap pain
1177.HK
-
CSPC Pharma taps R&D superstar in quest for new breakout drugs
1093.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
Hutchmed scores U.S. success with cancer drug, but profits still dip
HCM.US 0013.HK
-
Clinical trials come up short again for Alphamab Oncology
9966.HK
